Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

  • There is currently no data for N4P

Holding(s) in Company

14 Jul 2016 11:45

RNS Number : 2145E
Onzima Ventures PLC
14 July 2016
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

ONZIMA VENTURES PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Ö

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

MYLES MCNULTY

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

14 July 2016

6. Date on which issuer notified:

14 July 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

6%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

ORD

9,700,000

9,700,000

11,000,000

11,000,000

6.05%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

11,000,000

6.05%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

MYLES MCNULTY

15. Contact telephone number:

07826 927608

 

 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

MYLERS HENRY MCNULTY

Contact address

(registered office for legal entities)

 

62A ST. ANN'S HILL, LONDON, SW18 2SB

Phone number & email

 

07826 927608

MYLES_MCNULTY@BTINTERNET.COM

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Contact address

 

Phone number & email

 

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FCA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLRIMMTMBIBBTF
Date   Source Headline
17th Mar 202612:14 pmRNSResult of General Meeting and Change of Name
27th Feb 20267:00 amRNSNotice of GM and Proposed Change of Name
24th Feb 20267:00 amRNSCEO Appointment & Name Change Thalia Therapeutics
17th Dec 20257:00 amRNSBusiness and Operational Update
25th Sep 20257:00 amRNSInterim Results
23rd Sep 20257:00 amRNSPartnership with University of Strathclyde’s CMAC
22nd Sep 20257:00 amRNSN4 Pharma’s Nuvec® Targets Lung Cancer Cells
19th Sep 20257:00 amRNSNotice of Results, Analyst & Investor Presentation
11th Sep 20257:00 amRNS-RInvestor Event and Presentation
30th Jul 20251:55 pmRNS-RArticle on Nuvec®’s Potential in RNA Therapeutics
14th Jul 20257:00 amRNS-RInvestor Webinar
8th Jul 20257:00 amRNSDirectorate Change
30th Jun 20252:15 pmRNSResult of AGM
30th Jun 20257:00 amRNSAGM Statement
25th Jun 20257:00 amRNS-RInsight Event for Retail Investors
6th Jun 20257:00 amRNSFinal Results, Annual Report and Notice of AGM
27th May 20257:00 amRNS-REstablishment of New Senior Leadership Team
23rd May 202512:37 pmRNSTR-1: Notification of major holdings
21st May 20254:11 pmRNSHolding(s) in Company
15th May 20253:13 pmRNSChange of Registered Address
12th May 20257:00 amRNSN4 101 In Vivo Study Results
9th May 20258:24 amRNSHolding(s) in Company
29th Apr 20254:25 pmRNSHolding(s) in Company
29th Apr 202511:05 amRNSHolding(s) in Company
28th Apr 20252:30 pmRNSHolding(s) in Company
23rd Apr 20252:32 pmRNSTR-1: Standard form notification of major holdings
22nd Apr 202511:56 amRNSResult of General Meeting
4th Apr 20257:08 amRNSPosting of Circular and Notice of General Meeting
1st Apr 20254:08 pmRNSPlacing and Subscription to raise £1,750,000
18th Feb 202512:34 pmRNSHolding(s) in Company
7th Feb 20257:00 amRNS-RInvestor Webinar
27th Jan 20257:00 amRNS-RInvestor Webinar
16th Jan 20257:00 amRNS-RN4 Pharma Non-Executive Director Q&A
8th Jan 20257:00 amRNSDirectorate Changes
12th Dec 20247:00 amRNSN4 101 In Vitro Results
4th Dec 20247:00 amRNSNew Patent Filing
28th Nov 20247:00 amRNSGrant of Options
24th Sep 20247:00 amRNSInterim Results
17th Sep 20248:04 amRNSSRI Research Update
9th Sep 20247:00 amRNSDirector Appointment
23rd Aug 20248:30 amRNSChange of Auditor
20th Aug 20247:00 amRNSSRI Research Update
3rd Jul 20247:00 amRNSNanogenics Update
28th Jun 20247:00 amRNSTotal Voting Rights
19th Jun 20247:00 amRNSHolding(s) in Company
18th Jun 202412:34 pmRNSHolding(s) in Company
13th Jun 20244:52 pmRNSHolding(s) in Company
11th Jun 202411:16 amRNSNew Corporate Presentation
7th Jun 202410:18 amRNSPlacing and Subscription to raise £630,000
23rd May 20244:09 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.